News › Clinical Practice, Industry News, Patient Care

Non-Melanoma Treatment Markets Heat Up

November 27, 2017

Melanoma is not the only skin cancer—other diseases such as squamous and basal cell carcinoma are dangerous in their own right, and are on the rise. According to new research from Persistence Market Research, the treatment markets for non-melanoma skin cancer treatments are expanding—analysts expect the overall market to exceed $4.7 billion by the end of 2025.
The most common type of skin cancer, basal cell carcinoma can be recognized by dome-shaped skin growths, shiny pink or red patches, or waxy pale growths that resemble a scar. Squamous cell carcinoma, on the other hand, is likely to present as sores that heal and return, do not heal at all, flat red patches or rough-feeling bumps on the skin.
Read more at Skin Inc >>  

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics Refreshes Allergan Partner Privileges to Better Support Today’s Modern Aesthetics Practices
    • Galderma Receives EU Approval for Restylane Shaype: Bone-Mimicking Hyaluronic Acid Injectable for Chin
    • Merz Aesthetics’ Ultherapy PRIME Gains FDA Clearance for Knee Skin Laxity
    • USA Payments Becomes Gold Vendor Affiliate with the American Med Spa Association
    • FDA Accepts Supplemental Biologics License Application for Botox Cosmetic for Masseter Muscle Prominence
Advertisement